Home Other Building Blocks Zatebradine

Zatebradine

CAS No.:
85175-67-3
Catalog Number:
AG00G3RO
Molecular Formula:
C26H36N2O5
Molecular Weight:
456.5744
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
99%
1 week
United States
$175
- +
10mg
99%
1 week
United States
$244
- +
50mg
99%
1 week
United States
$873
- +
Product Description
Catalog Number:
AG00G3RO
Chemical Name:
Zatebradine
CAS Number:
85175-67-3
Molecular Formula:
C26H36N2O5
Molecular Weight:
456.5744
MDL Number:
MFCD00867014
IUPAC Name:
3-[3-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one
InChI:
InChI=1S/C26H36N2O5/c1-27(13-9-19-7-8-22(30-2)23(15-19)31-3)11-6-12-28-14-10-20-16-24(32-4)25(33-5)17-21(20)18-26(28)29/h7-8,15-17H,6,9-14,18H2,1-5H3
InChI Key:
KEDQCFRVSHYKLR-UHFFFAOYSA-N
SMILES:
COc1ccc(cc1OC)CCN(CCCN1CCc2c(CC1=O)cc(c(c2)OC)OC)C
UNII:
TV27RY5876
Properties
Complexity:
591  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
456.262g/mol
Formal Charge:
0
Heavy Atom Count:
33  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
456.583g/mol
Monoisotopic Mass:
456.262g/mol
Rotatable Bond Count:
11  
Topological Polar Surface Area:
60.5A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.6  
Literature
Title Journal
Why are most phospholipidosis inducers also hERG blockers? Archives of toxicology 20171201
The effects of jaspamide on human cardiomyocyte function and cardiac ion channel activity. Toxicology in vitro : an international journal published in association with BIBRA 20130301
Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG. Journal of molecular and cellular cardiology 20120501
Characterization of HCN and cardiac function in a colonial ascidian. Journal of experimental zoology. Part A, Ecological genetics and physiology 20111001
Design, synthesis, and preliminary biological evaluation of new isoform-selective f-current blockers. Journal of medicinal chemistry 20100923
8-OH-DPAT prevents cardiac arrhythmias and attenuates tachycardia during social stress in rats. Physiology & behavior 20090216
[Effects of zatebradine on the course of experimental myocardial infarction under long-term treatment conditions in rats]. Eksperimental'naia i klinicheskaia farmakologiia 20080101
A pharmacological model for calcium overload-induced tachycardia in isolated rat left atria. European journal of pharmacology 20071208
Three different bradycardic agents, zatebradine, diltiazem and propranolol, distinctly modify heart rate variability and QT-interval variability. Pharmacology 20070101
Bradycardic and proarrhythmic properties of sinus node inhibitors. Molecular pharmacology 20060401
[Selective I(f) channel inhibition: an alternative for treating coronary artery disease?]. Herz 20060201
Characterization of the human HCN1 channel and its inhibition by capsazepine. British journal of pharmacology 20041001
Role of force--frequency relation during AV-block, sinus node block and beta-adrenoceptor block in conscious animals. Basic research in cardiology 20040901
Heart rate reduction by zatebradine reduces infarct size and mortality but promotes remodeling in rats with experimental myocardial infarction. American journal of physiology. Heart and circulatory physiology 20040401
The impact of organic inhibitors of the hyperpolarization activated current (Ih) on the electroretinogram (ERG) of rodents. Archives italiennes de biologie 20040301
A simulation analysis on mechanisms of damped oscillation in retinal rod photoreceptor cells. Vision research 20030901
(+/-)-2-(3-Piperidyl)-1,2,3,4-tetrahydroisoquinolines as a new class of specific bradycardic agents. Bioorganic & medicinal chemistry letters 20030707
Sinus tachyarrhythmias and the specific bradycardic agents: a marriage made in heaven? Journal of cardiovascular pharmacology and therapeutics 20030601
Effects of changing heart rate on electrophysiological and hemodynamic function in the dog. Life sciences 20030314
Multiple inhibitory effects of zatebradine (UL-FS 49) on the electrophysiological properties of retinal rod photoreceptors. Pflugers Archiv : European journal of physiology 20020201
Parallel solid-phase synthesis of zatebradine analogues as potential I(f) channel blockers. Bioorganic & medicinal chemistry letters 20010903
Intraretinal analysis of the a-wave of the electroretinogram (ERG) in dark-adapted intact cat retina. Visual neuroscience 20010101
Increases in inotropic state without change in heart rate: combined use of dobutamine and zatebradine in conscious dogs. European journal of pharmacology 19961205
Effects of zatebradine on ouabain-, two-stage coronary ligation- and epinephrine-induced ventricular tachyarrhythmias. European journal of pharmacology 19960411
Addition of zatebradine, a direct sinus node inhibitor, provides no greater exercise tolerance benefit in patients with angina taking extended-release nifedipine: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. The Zatebradine Study Group. Journal of the American College of Cardiology 19950801
Zatebradine attenuates cyclic AMP-related positive chronotropic but not inotropic responses in isolated, perfused right atria of the dog. Clinical and experimental pharmacology & physiology 19950101
Zatebradine, a specific bradycardic agent, enhances the positive inotropic actions of dobutamine in ischemic myocardium. Journal of the American College of Cardiology 19940101
Effect of zatebradine on contractility, relaxation and coronary blood flow. Journal of the American College of Cardiology 19930201
Specific bradycardic agents, a new therapeutic modality for anesthesiology: hemodynamic effects of UL-FS 49 and propranolol in conscious and isoflurane-anesthetized dogs. Anesthesiology 19871101
Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-][2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new 'specific bradycardic agent'. European journal of pharmacology 19840903
Properties